Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study

被引：5
|
作者：
Agarwal, N. [1 ]
Brugarolas, J. [2 ]
Ghatalia, P. [3 ]
George, S. [4 ]
Haanen, J. B. A. G. [5 ]
Gurney, H. P. [6 ]
Ravilla, R. [7 ]
Van der Veldt, A. A. M. [8 ]
Beuselinck, B. [9 ]
Pokataev, I. [10 ]
Suelmann, B. B. [11 ]
Tuthill, M. [12 ]
Vaena, D. [13 ]
Zagouri, F. [14 ]
Wu, J. [15 ]
Liu, Y. [15 ]
Perini, R. [15 ]
Merchan, J. R. [16 ]
Atkins, M. B. [17 ]
机构：
[1] Huntsman Canc Inst, Oncol Internal Med Dept, Salt Lake City, UT USA
[2] Univ Texas Southwestern Med Ctr, Internal Med Hematol Oncol, Dallas, TX USA
[3] Fox Chase Canc Ctr, Hematol Oncol, Philadelphia, PA USA
[4] Roswell Pk Canc Inst, Oncol, Buffalo, NY USA
[5] Netherlands Canc Inst, Oncol, Amsterdam, Netherlands
[6] Macquarie Univ, Oncol, Sydney, NSW, Australia
[7] Albany Canc Ctr, Oncol, New York Oncol Hematol, Albany, NY USA
[8] Erasmus MC, Oncol, Rotterdam, Netherlands
[9] UZ Leuven, Oncol, Leuven, Belgium
[10] City Clin Oncol Hosp 1, Oncol, Moscow, Russia
[11] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands
[12] Oxford Univ Hosp NHS Fdn Trust, Oncol & Hematol, London, England
[13] West Canc Ctr & Res Inst, Oncol, Germantown, TN USA
[14] Alexandra Reg Gen Hosp, Oncol, Athens, Greece
[15] Merck & Co Inc, Oncol, Rahway, NJ USA
[16] Univ Miami Hosp & Clin, Oncol, Sylvester Canc Ctr, Canc Res Serv, Miami, FL USA
[17] Georgetown Univ, Oncol, Med Ctr, Washington, DC USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1111
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1881O
引用
收藏
页码：S1011 / S1011
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF TWO NEOADJUVANT STRATEGIES WITH BEVACIZUMAB IN LOCALLY ADVANCED RESECTABLE RECTAL CANCER: INTERIM RESULTS OF A RANDOMIZED, NON-COMPARATIVE PHASE II STUDY
    Bosset, J.
    Mantion, G.
    Andre, T.
    Boudghene, F.
    Piard, F.
    Mornex, F.
    Maingon, P.
    Adenis, A.
    Piutti, M.
    Borg, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 206 - 206
  • [32] Plitidepsin in patients with advanced renal cancer (RCC):: Results of an exploratory phase II trial
    Climent, Miguel A.
    Schoffski, Patrick
    Paz-Ares, Luis
    Rivera, Fernando
    Bezares, Susana
    Pico, Cesar
    Tabernero, Josep M.
    ANNALS OF ONCOLOGY, 2006, 17 : 147 - 147
  • [33] Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
    Mascarenhas, John
    Higgins, Brian
    Anders, Doreen
    Burbury, Kate
    El-Galaly, Tarec Christoffer
    Gerds, Aaron T.
    Gupta, Vikas
    Kovic, Bruno
    Maffioli, Margherita
    Mesa, Ruben
    Palmer, Jeanne M.
    Passamonti, Francesco
    Rambaldi, Alessandro
    Ross, David M.
    Vannucchi, Alessandro M.
    Yacoub, Abdulraheem
    BLOOD, 2020, 136
  • [34] Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results
    Tannir, N.
    Wong, Y.
    Kollmannsberger, C.
    Ernstoff, M. S.
    Perry, D. J.
    Appleman, L. J.
    Posadas, E.
    Qian, J.
    Ricker, J. L.
    Michaelson, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Preliminary efficacy and safety results of masitinib administered, front line in patients with advanced GIST. A phase II study
    Bui, B. N.
    Blay, J.
    Duffaud, F.
    Hermine, O.
    Hermine, O.
    Le Cesne, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] A phase II study of depsipeptide (Dep) in patients (pts) with metastatic renal cell cancer (RCC)
    Stadler, WM
    Swerdloff, JN
    Margolin, K
    McCulloch, B
    Thompson, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 420S - 420S
  • [37] A phase II study of IV gemcitabine (G) and oral capecitabine (C) in patients (pts) with advanced renal cell cancer (RCC): Results of Southwest Oncology Group study 0312
    Van Veldhuizen, P. J.
    Hussey, M.
    Lara, P. N.
    Gumerlock, P. H.
    Clark, J.
    Lange, M. K.
    Crawford, E. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy.
    Posadas, E. M.
    Tannir, N. M.
    Wong, Y.
    Ernstoff, M. S.
    Kollmannsberger, C. K.
    Qian, J.
    Ansell, P. J.
    McKeegan, E. M.
    Mckee, M. D.
    Ricker, J. L.
    Carlson, D. M.
    Michaelson, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)
    Mulders, P.
    Hawkins, R.
    Nathan, P.
    de Jong, I.
    Osanto, S.
    Porfiri, E.
    Protheroe, A.
    Mookerjee, B.
    Pike, L.
    Gore, M. E.
    EJC SUPPLEMENTS, 2009, 7 (03): : 21 - 21
  • [40] Phase II study of CC-5013 in patients (pts) with renal cell cancer (RCC).
    Chapa, P
    Rawat, A
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 446S - 446S
12345